Manuela Pelmus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manuela Pelmus has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Mark Basik
Gerald Bronfman Department of Oncology, McGill University, QC, Canada
27 shared publications - Jean-Francois Boileau
Department of Surgery and Gerald Bronfman Oncology, Jewish General Hospital, Segal Cancer, McGill University, Montréal, QC, Canada
26 shared publications - Adriana Aguilar-Mahecha
McGill University 1 Lady Davis Institute Montreal, Canada
25 shared publications - Josiane Lafleur
Jewish General Hospital 2 Segal Cancer Center, Lady Davis Institute Montreal, Canada
25 shared publications - Kathryn Bozek
McGill University 1 Lady Davis Institute Montreal, Canada
25 shared publications - Luca Cavallone
Jewish General Hospital 2 Segal Cancer Center, Lady Davis Institute Montreal, Canada
25 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S6. Statistics on protocol validation.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S6. Statistics on protocol validation.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S9. Fractional abundance differences in the post-surgical time points.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S9. Fractional abundance differences in the post-surgical time points.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S3. Prognostic performance of additional adjuvant capecitabine.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S3. Prognostic performance of additional adjuvant capecitabine.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S4. Within run assay precision.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S4. Within run assay precision.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S8. Raw fractional abundance for each variant in patient plasma, normal plasma and tumor tissue.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S8. Raw fractional abundance for each variant in patient plasma, normal plasma and tumor tissue.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S9. Corrected Fractional Abundance for each variant.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Table S9. Corrected Fractional Abundance for each variant.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S7. Prognostic performance of the changes in ctDNA detection from the post-neoadjuvant, pre-surgical time point (T1) to the first post-surgical time point (T2).
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S7. Prognostic performance of the changes in ctDNA detection from the post-neoadjuvant, pre-surgical time point (T1) to the first post-surgical time point (T2).
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S10. CtDNA detection is an independent prognostic biomarker.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S10. CtDNA detection is an independent prognostic biomarker.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Purpose:Patients with triple-negative breast cancer (TNBC) who have residual tumor at surgery [nonpathologic complete response or (non-pCR)] after neoadjuvant chemotherapy (NAC) have a poor prognosis. In these cases, adjuvant chemotherapy with capecitabine improves disease-free survival in ∼15% of patients. Identifying those who would benefit from such additional therapy remains a critical need.Experimental Design:In the TRICIA trial, 92 patients with non-pCR provided plasma before surgery and after NAC (T1), after surgery (T2), during adjuvant capecitabine therapy (T3), and late after surgery following completion of adjuvant treatment (T4). The sensitivity, specificity, and predictive values of a tumor-informed digital droplet–based ctDNA detection assay were measured with a median follow-up of 38 months.Results:ctDNA was detected in 97% of patients before clinical relapse. We confirmed that the lack of detection of ctDNA at the post-NAC/preoperative (T1) time point is highly prognostic, with 95% distant-disease relapse-free survival. The detection of ctDNA in patients with significant residual tumor (Residual Cancer Burden 2/3) was also highly prognostic and our test performed with 100% sensitivity and 100% specificity in RCB 3 patients. We measured three time points before, during, and after capecitabine treatment and found that capecitabine treatment was associated with clearance of ctDNA in 41% of cases, and clearance was associated with good prognosis.Conclusions:These findings suggest that ctDNA testing using digital droplet PCR assays in an academic hospital-based context can reliably identify a very low-risk group of patients with non-pCR TNBC.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Purpose:Patients with triple-negative breast cancer (TNBC) who have residual tumor at surgery [nonpathologic complete response or (non-pCR)] after neoadjuvant chemotherapy (NAC) have a poor prognosis. In these cases, adjuvant chemotherapy with capecitabine improves disease-free survival in ∼15% of patients. Identifying those who would benefit from such additional therapy remains a critical need.Experimental Design:In the TRICIA trial, 92 patients with non-pCR provided plasma before surgery and after NAC (T1), after surgery (T2), during adjuvant capecitabine therapy (T3), and late after surgery following completion of adjuvant treatment (T4). The sensitivity, specificity, and predictive values of a tumor-informed digital droplet–based ctDNA detection assay were measured with a median follow-up of 38 months.Results:ctDNA was detected in 97% of patients before clinical relapse. We confirmed that the lack of detection of ctDNA at the post-NAC/preoperative (T1) time point is highly prognostic, with 95% distant-disease relapse-free survival. The detection of ctDNA in patients with significant residual tumor (Residual Cancer Burden 2/3) was also highly prognostic and our test performed with 100% sensitivity and 100% specificity in RCB 3 patients. We measured three time points before, during, and after capecitabine treatment and found that capecitabine treatment was associated with clearance of ctDNA in 41% of cases, and clearance was associated with good prognosis.Conclusions:These findings suggest that ctDNA testing using digital droplet PCR assays in an academic hospital-based context can reliably identify a very low-risk group of patients with non-pCR TNBC.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S4. Pearson Correlation of VAF for each tumor variant from WES and its corresponding validated ddPCR assay.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
Supplementary Figure S4. Pearson Correlation of VAF for each tumor variant from WES and its corresponding validated ddPCR assay.